VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours by Ohta, Y et al.
Asbestos had been widely used for centuries before a causal rela-
tionship between malignant pleural mesothelioma (MPM) and
exposure to asbestos was confirmed. Although the use of asbestos
has recently been restricted, the incidence of MPM remains high
and is steadily increasing due to the long latent period for MPM
after the exposure to asbestos (Mossman et al, 1996). Advanced
MPM remains an aggressive and highly lethal disease due to its
marked resistance to conventional treatments, including surgical
resection, chemotherapy and radiotherapy.
Angiogenesis is crucial for the proliferation of tumour cells, and
anti-angiogenic therapy is a promising strategy aimed at inhibiting
tumour growth, invasion and metastasis (Folkman et al, 1995).
Among the many reported angiogenic factors, vascular endothelial
growth factor (VEGF) is the most powerful endothelial cell-
specific mitogen associated with tumour neovascularization.
While a number of investigators have reported the direct relation-
ship between microvessel density (VD) and VEGF expression
within a variety of tumours (Toi et al, 1994; Mattern et al, 1995;
Samoto et al, 1995; Takahashi et al, 1995), recent studies also
suggest that VEGF type B, C, D and E are novel regulators of
endothelial cell proliferation (Grimmond et al, 1996; Joukov et al,
1996; Lee et al, 1996; Olofsson et al, 1996; Yamada et al, 1997;
Meyer et al, 1999). Interestingly, the function of VEGF-C appears
to extend to the lymphatic system where it serves as a ligand for
fms-like tyrosine kinase 4 (flt-4) (Kukk et al, 1996; Jeltsch et al,
1997). However, lymphangiogenesis within tumours has not been
documented.
For MPM, little information on tumour angiogenesis is avail-
able. In this study, we assessed the expression of VEGF, VEGF-C
and VEGFRs (KDR, flt-1 and flt-4) in human MPM cell lines,
MPM tumour samples and normal pleural tissue. We used the
reverse transcriptase polymerase chain reaction technique (RT-
PCR) to assess the expression of each factor, and we also assessed
the VD and microlymphatic vessel density (LVD) within tumours
using immunohistochemistry for factor VIII and enzyme-histo-
chemistry for 5¢-nucleotidase (5¢-NA) respectively. The expres-
sion of the associated angiogenic factors and receptors was also
determined. Clinical correlations of angiogenesis with survival
from treatments for the patients was also performed.
MATERIALS AND METHODS
Cell lines and tissue samples
The human malignant mesothelioma cell lines (H-meso, H2818,
H2591 and H2595) used in this study were all developed from
tumours diagnosed using a well-defined panel of immunohisto-
chemical markers (Pass et al, 1995). H-meso is commercially
available (Biomeasure, Hopkinton, MA, USA), while H2818,
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H2591 and H2595 were developed from resected MPM tumours at
the National Cancer Institute (Bethesda, MD, USA) (Pass et al,
1995). A human fibrosarcoma cell line (HT1080) was used as a
positive control for VEGF, VEGF-C, flt-1 and flt-4, while
HUVEC was used for kinase insert domain-containing receptor
(KDR). Cell lines were maintained in RPMI-1640 media (Gibco-
BRL, Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (FBS), 2 mML -glutamine, 10 mM HEPES buffer,
500 units ml—1 penicillin and 500 units ml—1 streptomycin at 37°C
under a humidified atmosphere of 5% carbon dioxide. Five normal
pleural tissue samples were obtained from patients with non-
cancerous disease (either for repair of hiatus hernia or diagnosis of
pulmonary infiltrates). In all these cases, the resected pleural tissue
was confirmed to be free of malignancy by pathological examina-
tion. And 54 malignant mesothelioma tumours were randomly
chosen from a bank of snap-frozen samples collected by one of us
(HIP). For tumour samples, consecutive 6-mm cryosections were
cut from the invasive tumour margin for immunohistochemical
and enzyme-histochemical studies. The pathologic classification
of each sample was confirmed by review of haematoxylin and
eosin (H&E)-stained sections. The pathological MPM subtypes
identified were: epithelial (E), 44; sarcomatous (S), 4; and mixed
(M), 6. According to the new international TNM staging system
(Rusch, 1996), 50 cases could be classified based on pathological
findings [stage II in nine (E, 7; S, 2), III in 36 (E, 28; S, 2; M, 6)
and IV in five (E, 4; M, 1)].
RT-PCR analysis
Total RNA was extracted from the human mesothelioma cell lines,
control cell lines (HT1080 and HUVEC), normal pleural tissues,
and each resected MPM tumour using TRIzol (Life Technologies,
Inc., Grand Island, NY, USA) according to the standard acid—guani-
dium—phenol—chloroform method. Total RNA (1 mg) was denatured
together with oligo-dT primer (10 pmol) for 15 min at 68°C. After
this was chilled on ice for 5 min, poly-adenosine (poly-A) RNA was
reverse-transcribed at 42°C for 90 min in RT solution (50 mM
Tris—HCl (hychochloric acid), pH 8.3; 40 mM potassium chloride
(KCl); 8 mM magnesium chloride (MgCl2); 0.5 mM each dNTP;
225 mg ml—1 bovine serum albumin; 5 mM dithiothreitol; 20 units
RNasin (Life Technologies, Inc., Grand Island, NY, USA) and
4 units AMV reverse transcriptase (Gibco-BRL, Gaithersburg, MD,
USA)). The cDNA was incubated at 95°C for 5 min to inactivate
the reverse transcriptase, and served as the template for PCR
amplification. For quantitative evaluation of the amplified product,
PCR encompassing 20—40 cycles was preliminarily performed to
determine the most suitable number of amplifications for each
factor. PCR was performed after adding 80 ml of PCR mixture (50
mM Tris—HCl, pH 8.3; 40 mM KCl; 8 mM MgCl2; 0.5 mM each
dNTP; 50 pmol of each the sense and the antisense primer; 2.5 units
of Taq polymerase (Takara, Kyoto, Japan)). Each cycle consisted of:
1 min at 94°C, 1 min at 58°C and 2 min at 72°C for VEGF, flt-1 and
KDR; and 1 min at 94°C, 1 min at 52°C and 1.5 min at 72°C for
VEGF type C, flt-4 and b-actin. PCR primers used and PCR condi-
tions are shown in Table 1. The PCR products were electrophoresed
through a 1.0% agarose gel (4-mm thick). The gel was fluorescently
stained in SYBR Green I stain Solution (FMC Bio-Products,
Rockland, ME, USA) at a 1:10 000 dilution in 1 ´ TAE buffer
(pH 7.2) for 30 min. The intensity of the PCR product bands was
measured by Storm“ image analyser (Molecular Dynamics, Inc.,
Sunnyvale, CA, USA). Each expression was standardized using the
b-actin signal as an internal control and a densitometry index
defined. For negative control of each factor, PCR was done
excepting the template cDNA.
Enzyme-histochemistry
An enzyme-histochemical reaction for 5¢-NA was done according
to the leading method of Wachstein et al (1954). Briefly, cryostat
sections were fixed with 5% paraformaldehyde for 10—60 min (10,
20, 30, 40, 50 and 60 min for each sample). This step-wise fixation
was carried out in order to discover the appropriate conditions to
maximally exhibit 5¢-NA activity in microlymphatic vessels
compared to that in blood vessels. Next, after washing with water
for 5 min, sections were treated with an enzyme reaction for 2 h
at 37°C using a substrate mixture (20 ml of 0.2 M Tris—maleate
buffer (pH 7.2), 25 mg adenosine-5-monophosphate (Sigma,
St Louis, MO, USA), 20 mg tetramisole (Sigma, St Louis, MO,
USA), 3.5 mg sucrose, 5 ml 0.1 M magnesium sulphate, 3 ml of
2% Pb(NO3)2, 20 ml water). After the sections were washed with
water for 15 min, they were reacted with a 1% ammonium
sulphide solution (Sigma, St Louis, MO, USA) for 2 min. The
sections were counterstained with methyl green and mounted
using glycerol (Sigma, St Louis, MO, USA).
Immunohistochemistry
Consecutive cryostat sections were used for the immunohistochem-
ical assessment of VD. The primary antibodies used in this study
Table 1 Nucleotide sequences of the primers used and their PCR conditions.
Angiogenic factors  Primer sets PCR cycle Product size (bp)
VEGF 5¢-GAAGTGGTGAAGTTCATGGATGTC-3¢ (sense) 30 408 (VEGF121)
5¢-CGATCGTTCTGTATCAGTCTTTCC-3¢ (antisense) 541 (VEGF165)
613 (VEGF185)
VEGF-C 5¢-CATGTACGAACCGCCAG-3¢ (sense) 25 320
5¢-TTGGCTGTTTGGTCATTGGC-3¢ (antisense)
Flt-1 5¢-GAGAATTCACTATGGAAGATCTGATTTCTTACAGT-3¢ (sense) 30 1098
5¢-GAGCATGCGGTAAAATACACATGTGCTTCTAG-3¢ (antisense)
Flt-4 5¢-AGCCATTCATCAACAAGCCT-3¢ (sense) 25 298
5¢-GGCAACAGCTGGATGTCATA-3¢ (antisense)
KDR 5¢-TATAGATGGTGTAACCCGGA-3¢ (sense) 30 555
5¢-TTTGTCACTGAGACAGCTTGG-3¢ (antisense)were an anti-factor VIII rabbit polyclonal antibody at a 1:200 dilu-
tion (Dako Corp., Carpinteria, CA, USA) and an anti-flt-4 rabbit
polyclonal antibody at a 1:200 dilution (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). The staining was done by the
immunoperoxidase technique. After air-drying for 10 min sections
were fixed with acetone for 10 min at —20°C. Then the cryostat
sections were washed in Dulbecco￿s phosphate-buffered saline
(pH 7.2) without calcium or magnesium (PBS—) and endogenous
peroxidase was blocked by treatment with 0.3% hydrogen peroxide
in methanol for 30 min. After washing with PBS—, the sections
were blocked with normal goat serum diluted tenfold with PBS— for
20 min at room temperature. After washing with PBS—, the sections
were reacted with primary antibody for 2 h, then washed with
PBS— and reacted with biotin-labelled anti-rabbit immunoglobulin
(Vector Laboratories, Burlingame, CA, USA) for 30 min at
room temperature. After sections were washed with PBS—,
avidin—biotin—peroxidase complex was added and developed by
3-3¢ diaminobenzidine (Sigma, St Louis, MO, USA) with 0.03%
hydrogen peroxide. Counterstaining was done with methyl green.
The negative control used all of the reagents except for the primary
antibody. As for the flt-4, specificity of the staining was tested
using blocking peptide (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA).
Assessment of vessel density
LVD was determined by enzyme-histochemistry for 5¢-NA, and
VD was determined by immunohistochemistry for factor VIII. For
the assessment of LVD, we initially identified candidate lymphatic
vessels and blood vessels in consecutive H&E-stained and
immunohistochemically stained sections for each sample. Then,
we chose the most appropriate enzyme-histochemical stained
section among the six sections with different fixation times for
each sample, i.e. the slides with maximal 5¢-NA activity in
lymphatic vessels compared to in blood vessels. The vessel densi-
ties were assessed blindly by two investigators according to the
method previously described by Weidner et al (1991). After the
areas of the highest vascularization were chosen under low power
(100 ´ magnification), vessel counts within tumours were done in
the three fields at 400 ´ magnification for VD and at 200 ´ magni-
fication for LVD. The average counts of the three fields were
recorded and the mean of the two investigators findings was used
for the final VD.
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Figure 1 RT-PCR analysis of VEGF, VEGF-C and their receptors (KDR,
flt-1 and flt-4) in human mesothelioma cell lines (A), normal pleural tissue (B)
and resected human malignant mesothelioma tumour samples (C). High
expression of VEGF, VEGF-C and VEGFRs mRNA was recognized in human
mesothelioma cell lines. Compared with the expression in the five normal
pleural tissues, VEGF-C and flt-4 mRNA expression levels were greater in
tumour tissuesAngiogenesis in malignant mesothelioma 57
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Statistics
Differences in densitometry indices were analysed using the
Mann—Whitney U-test. The Spearman￿s rank correlation coeffi-
cient test was used to examine the associations between different
variables. To assess the prognostic effect on overall survival,
VEGF, VEGF-C, VEGFRs, VD and LVD were classified as high
or low expressing group relative to the mean values of densito-
metry indices in resected tumours. Two combination factors,
COM-VEGF and COM-VEGF-C, were defined to reduce the
dimensionality of the independent variables list. The COM-VEGF
factor was defined as ￿positive￿ if two or more of the three associ-
ated variables (VEGF, flt-1, KDR) were strongly expressed,
￿negative￿ if otherwise. The COM-VEGF-C factor was defined
as ￿positive￿ if both VEGF-C and flt-4 were strongly expressed,
￿negative￿ if otherwise. Survival curves were obtained by the
Kaplan—Meier method, and compared univariately by log-rank
tests. The effects of age (over vs under 50 years), gender, patho-
logical stage (I, II, vs III, IV), pathological subtype (epithelial
vs others), nodal status (positive vs negative), VEGF, VEGF-C,
VEGFRs, VD and LVD on overall survival were assessed multi-
variately using the Cox proportional hazard regression along with
a step-wise procedure for variable selection. Factors with P-value
< 0.10 were included in the final model.
Table 2 Expression of VEGF, VEGF-C and VEGFRs mRNA in malignant
mesothelioma tumours
Percentage of positive aPercentage of
tumours (cases) overexpression (cases)
VEGF 75.9 (41/54) 31.5 (17/54)
VEGF-C 85.2 (46/54) 66.7 (36/54)
flt-1 74.1 (40/54) 20.4 (11/54)
KDR 90.7 (49/54) 42.6 (23/54)
flt-4 96.3 (52/54) 59.3 (32/54)
a> each mean value of normal pleural tissue.
Table 3 The mean densitometry index of each factor in MPM tumours and
normal pleural tissue samples
MPM tumours (n = 54) Normal pleural tissue (n = 5)
VEGF-C 0.87 ± 0.15 0.16 ± 0.03
flt-4 1.24 ± 0.25 0.34 ± 0.07
KDR 1.73 ± 0.38 1.08 ± 0.23
VEGF 1.80 ± 0.41 1.80 ± 0.60
flt-1 0.50 ± 0.11 0.95 ± 0.46
10
9
8
7
6
5
4
3
2
1
0
f
l
t
-
4
0123456
VEGF-type C
r = 0.67
P = 0.0018
A
0123456
VEGF-type C
r = 0.63
P < 0.0001
B
35
30
25
20
15
10
5
0
L
V
D
0
r = 0.64
P = 0.0164
C 35
30
25
20
15
10
5
0
L
V
D
123456789 1 0
flt-4
r = 0.33
P = 0.0188
D 25
20
15
10
5
0
V
D
02468 1 0 1 2 1 4 1 6 1 8 2 0
VEGF121
Figure 2 Correlation (non-parametric) between VEGF-C and flt-4 mRNA expression (A), VEGF-C mRNA expression and LVD (B), flt-4 mRNA expression and
LVD (C) and VEGF mRNA expression and VD (D) within MPM tumoursRESULTS
Expression of VEGF, VEGF-C and VEGFRs in normal
pleural tissues, human mesothelioma cell lines and
resected mesothelioma tumours
High VEGF, VEGF-C and VEGFRs (KDR, flt-1 and flt-4) mRNA
expression was noted in all human MPM cell lines (Figure 1A). In
MPM tumours, the percentages of positive tumours were, VEGF,
75.9% (41/54 cases); VEGF-C, 85.2% (46/54); flt-1, 74.1% (40/54);
KDR, 90.7% (49/54); flt-4, 96.3% (52/54). The percentages of
tumours with higher expression compared to the mean values of
normal pleural tissues were 31.5% (17/54) for VEGF, 66.7% (36/54)
for VEGF-C, 20.4% (11/54) for flt-1, 42.6% (23/54) for KDR and
59.3% (32/54) for flt-4 (Table 2). Compared to the mean values in
resected tumours, higher densitometry index of VEGF was found in
two (case nos 2 and 5 in Figure 1B) and higher index of VEGF-C
was also recognized in two out of five normal pleural samples (case
nos 3 and 5 in Figure 1B). The sample data of resected tumour
specimens are shown in Figure 1C. Compared with normal pleural
tissues, the mean densitometry indexes of VEGF-C (0.87 ± 0.15 vs
0.16 ± 0.03) (± s.e.m.), flt-4 (1.24 ± 0.25 vs 0.34 ± 0.07) and KDR
(1.73 ± 0.38 vs 1.08 ± 0.23) tended to be greater in MPM tumours
(Table 3). Positive correlations were observed between VEGF-C
and flt-4 (P = 0.0018, r = 0.67, Figure 2A), VEGF and KDR
(P = 0.0002, r = 0.39), and VEGF and flt-1 (P = 0.0089, r = 0.27).
Immunohistochemically, flt-4 antigen was identified in the
cytoplasm of malignant pleural mesothelioma cells (Figure 3A)
and partly in vascular endothelial cells (Figure 3B).
LVD and VD within MPM tumour tissues
The 5¢-NA staining was limited to vessels in 31 of the 54 speci-
mens (57.4%). In these samples, fixation for 30—40 min was
optimal for highlighting 5¢-NA activity in lymphatic vessels while
suppressing 5¢-NA activity in blood vessels (Figure 4). In 23 cases
(42.6%), 5¢-NA staining was seen both in vessels and in tumour
cells or stromal elements. In 20 of these 23 cases, the intensity of
this non-specific staining was very low compared to that of the
lymphatics, and assessment of LVD was easily achieved.
However, in three cases, the intensity of non-specific staining
remained very high despite 60-min of fixation. In these three
cases, LVD was assessed by avoiding areas with high non-specific
activity. The mean VD and LVD were 10.9 ± 0.8 (range 0—31) and
9.1 ± 0.9 (range 1—24) respectively. LVD and VEGF-C mRNA
expression were strongly associated (P < 0.0001, r = 0.63, Figure
2B). There were also significant positive relationships between
LVD and flt-4 expression (P = 0.0164, r = 0.64, Figure 2C), and
VD and VEGF (P = 0.0188, r = 0.33, Figure 2D).
58 Y Ohta et al
British Journal of Cancer (1999) 81(1), 54–61 © 1999 Cancer Research Campaign
A
B
A
B
Figure 4 5¢-nucleotidase reaction of microvessels within tumours by
enzyme-histochemistry for 5¢-NA (A) and immunohistochemical staining for
factor VIII antigen (B) of the consecutive cryostat sections. Theoretically,
closed arrows show lymphatic vessels and open arrows show blood vessels.
Closed arrows in A were counted for LVD and both closed and open arrows
in B were counted for VD in this study. Scale bar, 40 mm
Figure 3 (A) Staining of flt-4 using polyclonal antibody in malignant pleural
mesothelioma tissue. Cytoplasmic staining was positive in tumour cells.
(B) Weakly staining of flt-4 was partly identified in vascular endothelial cellsAssociation with clinicopathological findings
Histopathological information on lymph node metastasis was avail-
able in 47 cases. The mean LVD and VD were 8.3 ± 1.0 and
10.9 ± 1.1 in node-positive cases (n = 30), and 10.2 ± 1.4 and
11.0  ± 1.5 in node-negative cases (n = 17) respectively. Nodal status
had no relationship with LVD (P = 0.1351) or VD
(P = 0.8856). VEGF and VEGF-C mRNA expression levels were
1.9 ± 0.6 and 0.8 ± 0.2, respectively, in node-positive cases, and
1.3 ± 0.2 and 0.9 ± 0.2, respectively, in node-negative cases. The
differences were not statistically significant. In stage III patients
with epithelial type who underwent standardized resections
(n = 28), the median survival of high and low VD groups were 11
and 17 months respectively. The 1-year survival rates for high and
low VD were 40.0% and 61.5% respectively. In this analysis, high
VD tended to correlate with poor survival (P = 0.0866, Figure 5).
Using all patients with standardized resections (n = 46), age, nodal
status, histological subtype, VEGF-C, flt-4, the COM-VEGF-C and
LVD had no impact on survival. As a result of multivariate analysis,
male, advanced stage (III and IV) and high VD were independent
negative prognostic indicators. The positive COM-VEGF also
showed weaker correlation with poor survival (Table 4).
DISCUSSION
Neovascularization has been shown to be necessary for tumour
growth and metastasis (Folkman, 1990). Although some contraries
exist, many studies have confirmed the negative impact of tumour
vascularization on prognosis (Chodak et al, 1980; Weidner et al,
1991; Macchiarini et al, 1992). Among the many reported angio-
genic factors, VEGF is the most powerful endothelial cell-specific
mitogen associated with tumour neovascularization. A number of
investigators have reported a significant relationship between VD
and VEGF expression in a variety of tumours (Toi et al, 1994;
Mattern et al, 1995, Samoto et al, 1995, Takahashi et al, 1995), and
overexpression of VEGF has been associated with poor prognosis
in some neoplasms (Toi et al, 1994; Takahashi et al, 1995).
However, little information is available on tumour angiogenesis in
malignant mesothelioma. Recently, Kumar-Singh et al (1997)
reported that VD in MPM tumours was significantly higher than
that in non-neoplastic mesothelium. They also reported that the
patients with highly vascularized tumours had a significantly
shorter survival than patients with poorly vascularized ones
(Kumar-Singh et al, 1997). In this study, higher densitometry
index of VEGF compared to the mean value of tumours was found
in two out of five normal pleural tissues. If pleura is a tissue with
relatively high VEGF, this particular condition may suit malignant
development. Among VEGFRs, the KDR and flt-4 expression
levels tended to be higher in the MPM tumours compared to
normal pleural tissues in this study. Although the percentage of
VEGF overexpression was not so high, our data confirmed that
VEGF expression was significantly associated with VD and the
expression of VEGFRs (KDR and flt-1) in MPM tumours.
Furthermore, among the 46 MPM patients undergoing standard-
ized resections, high VD was significantly associated with poor
survival. A combination factor with VEGF and its receptors (flt-1
and KDR), COM-VEGF, also had a weaker relationship with
outcome, yet the value only trends toward significance due to the
small sample size.
Most conventional immunohistochemistry methods for the detec-
tion of endothelial cells do not distinguish lymphatics from blood
vessels. In this study, we tried to assess the LVD within MPM
tumours using the enzyme-histochemistry assay for 5¢-NA based on
the leading method (Wachstein et al, 1954). 5¢-NA expression in
vascular endothelial cells varies according to vessel types (Turner et
al, 1987; Airas et al, 1997). That is, the activity of 5¢-NA is very high
in lymphatic endothelial cells, while it is very low or absent in blood
capillary endothelial cells (Turner et al, 1987). Therefore, this assay
has a great potential to discriminate neo-lymphatics from
neo-blood vessels after the adequate inhibition of its activity by
paraformaldehyde (Vetter et al, 1970; Ji et al, 1997). In normal
lymphatics, this enzyme activity appears to be necessary for the
growth and development of vessels (Ji et al, 1997), and has an
important role in the control of interactions between lymphocytes
and vascular endothelial cells (Airas et al, 1997). If this enzyme
activity is essential for the proliferation of lymphatic vessels, the
same condition may be expected in tumour-induced neo-vessels.
Although the significance of 5¢-NA activity in cancerous lesions is
not clear, this enzyme has been reported in some tumour tissues,
including seminoma, malignant fibrous histiocytoma, breast cancer
and renal cancer (Wachstein et al, 1954; Wood et al, 1986; Canbolat
et al, 1996; Durak et al, 1997). In this study, we have used this
method, for the first time, to study the microlymphatic vessel
density in MPM tumours and found that 5¢-NA staining was limited
to vessels in 31 of the 54 (57.4%) MPM tumour specimens. In
these samples, lymphatic vessel specificity was optimized by
paraformaldehyde fixation for 30—40 min. In 23 cases (42.6%),
5¢-NA staining was also noted in MPM tumour cells and within
stromal elements. In 20 out of these 23 cases, the intensity of the
non-vessel staining was less than that of the vessels, and LVD could
be assessed. In three cases with the intensity of non-specific
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Table 4 Cox proportional hazard regression analysis using 46 malignant
pleural mesothelioma patients with standardized resections
Hazard ratio P 95% CI
Gender 3.437 0.0067 1.409 – 8.384
Stage (I, II vs III, IV) 3.729 0.0091 1.387 – 10.025
VD 2.247 0.0326 1.070 – 4.719
*COM-VEGFa 0.400 0.0731 0.147 – 1.089
aA combination factor of VEGF, flt-1, and KDR. It was defined as ‘positive’ if
two or more of the three associated variables are strongly expressed.
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Figure 5 Kaplan–Meier survival plots in stage III patients with epithelial
type MPM who underwent standardized resections (n = 28). A tumour was
included in the high VD group if VD was greater than 11. High VD tended to
be associated with poor survival (P = 0.0866)staining, LVD was assessed by avoiding areas with high non-
specific activity. Under the condition that very little information is
available about the mechanisms of lymphangiogenesis, some
reports have recently suggested that the specific pathways involved
in lymphangiogenesis are different from those in hemangiogenesis
(Wilting et al, 1996; Oh et al, 1997). Among the VEGF family
members, the function of VEGF-C appears to extend to the
lymphatic system as a ligand for flt-4, and VEGF-C is suspected
to play an important role in lymphangiogenesis (Kukk et al, 1996;
Jeltsch et al, 1997; Oh et al, 1997). In this study, we identified a
strong positive relationship between VEGF-C mRNA expression
and LVD, and flt-4 expression and LVD in MPM, as well as a close
association between flt-4 and VEGF-C expression. Further, the
mean vessel count for VD that includes both blood and lymphatic
vessels was much greater than that for LVD. VD itself had no
relationship with VEGF-C and flt-4 expression levels in this study.
These results support the use of the enzyme-histochemistry method
based on 5¢-NA activity for assessment of lymphatics, and also
suggest that VEGF-C plays a key role in lymphangiogenesis in
MPM. In addtion, flt-4 expression, which has originally been found
in lymphatic endothelium (Kaipainen et al, 1995; Joukov et al,
1996), was high in both MPM cell lines used and resected tumour
tissues. Immunohistochemical staining revealed flt-4 expression in
MPM tumour cells except for some vascular endothelial cells. In
this study, it was difficult to clarify the correspondence between
endothelial cells with flt-4 expression and those with 5¢-NA activity
partly owing to the situation that mesothelioma cells themselves
expressed both flt-4 and 5¢-NA. Although the role of flt-4 in tumour
cells is not well known, flt-4 expression was confirmed in meso-
thelial cells (Hewett et al, 1996). This suggests a possibility that
mesothelioma cells express flt-4, and that VEGF-C may have some
role for the autocrine growth or proliferation of tumour cells.
In conclusion, our study suggests that VEGF and VEGF-C play
an important role in angiogenesis and lymphangiogenesis in MPM
tumours, and that VD has a significant impact on the overall
survival of MPM patients. The LVD assessed by enzyme-histo-
chemistry for 5¢-NA has no impact on nodal metastasis. However,
nodal status does not have a relation with outcome in our samples.
Therefore, a question remains whether VEGF and VEGF-C have a
relation with prognosis in cases where nodal status has a great
impact on survival. The potential roles of VEGF and VEGF-C in
lymphatic metastasis warrant further study.
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